Dianthus Therapeutics
DNTH
268 hedge funds and large institutions have $6.4B invested in Dianthus Therapeutics in 2026 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 117 increasing their positions, 68 reducing their positions, and 32 closing their positions.
94% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 32
72% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 68
24% more capital invested
Capital invested by funds: $5.18B → $6.4B (+$1.22B)
11% more funds holding
Funds holding: 241 → 268 (+27)
3% more call options, than puts
Call options by funds: $24.8M | Put options by funds: $24M
19.6% less ownership
Funds ownership: 139.86% → 120.26% (-20%)
38% less funds holding in top 10
Funds holding in top 10: 16 → 10 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$227M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$119M |
| 3 |
State Street
Boston,
Massachusetts
|
+$83.7M |
| 4 |
BlackRock
New York
|
+$82.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$55.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$219M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$70.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$55.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$54M |
| 5 |
CCM
Catalio Capital Management
New York
|
-$46.1M |
DNTH Hedge Fund Activity: Q2 2026 in Review
268 institutional investors reported a position in Dianthus Therapeutics (DNTH) for Q2 2026, worth a combined $6.4B — up 24% from $5.18B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new DNTH positions and 32 closed out — a net gain of 30 holders — while 117 added to existing stakes and 68 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $227M. The largest seller was RA Capital Management, exiting entirely with an estimated $219M sold.
- 268 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2026, up from 241 in Q1 2026.
- Funds reported $6.4B of Dianthus Therapeutics stock for Q2 2026, up 24% quarter-over-quarter.
- 62 funds opened new Dianthus Therapeutics positions in Q2 2026 and 32 closed out, a net change of +30 holders.
- The largest Dianthus Therapeutics buyer in Q2 2026 was T. Rowe Price Investment Management, an estimated $227M added.
- The largest Dianthus Therapeutics seller in Q2 2026 was RA Capital Management, an estimated $219M sold.
Based on aggregated 13F filings for Q2 2026.